Growing attempts to develop biomarkers to guide therapy within triple-negative breast cancer may lead to more effective regimens or to novel therapeutic targets.
Daniel G. Stover, MD
Advertisement
Articles by Daniel G. Stover, MD
Advertisement
Latest Updated Articles
Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast CancerPublished: May 2nd 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5